Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antiparasitic drugs >  Antimalarial drugs >  Primaquine diphosphate

Primaquine diphosphate

Basic information Safety Supplier Related

Primaquine diphosphate Basic information

Product Name:
Primaquine diphosphate
Synonyms:
  • 8-(4-amino-1-methylbutylamino)-6-methoxyquinoline diphosphate salt
  • PRIMAQUINEPHOSPHATE,USP
  • 4-pentanediamine, n(sup 4)-(6-methoxy-8-quinolinyl)- phosphate
  • 8-((4-amino-1-methylbutyl)amino)-6-methoxy-quinolin phosphate
  • Primaquine diphosphate salt, 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline diphosphate salt
  • 1,4-Pentanediamine, N(sup 4)-(6-methoxy-8-quinolinyl)-, phosphate (1:2)
  • N-(6-Methoxyquinolin-8-yl)pentane-1,4-diamine phosphoric acid
  • Quinoline, 8-((4-amino-1-methylbutyl)amino)-6-methoxy-, phosphate (1:2)
CAS:
63-45-6
MF:
C15H27N3O9P2
MW:
455.34
EINECS:
200-560-8
Product Categories:
  • Amines
  • Heterocycles
  • APIS
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
Mol File:
63-45-6.mol
More
Less

Primaquine diphosphate Chemical Properties

Melting point:
205-206 °C (dec.)(lit.)
storage temp. 
2-8°C
solubility 
water: soluble50mg/mL, clear, orange to red
Water Solubility 
moderately soluble
Merck 
13,7833
BRN 
3812133
BCS Class
1 (CLogP), 3 (LogP)
Stability:
Stable. Incompatible with strong oxidizing agents.
CAS DataBase Reference
63-45-6(CAS DataBase Reference)
More
Less

Safety Information

Hazard Codes 
T
Risk Statements 
25
Safety Statements 
45
RIDADR 
UN 2811 6.1/PG 3
WGK Germany 
3
RTECS 
VA9660000
10
HazardClass 
6.1(b)
PackingGroup 
III
HS Code 
29334900

MSDS

More
Less

Primaquine diphosphate Usage And Synthesis

Chemical Properties

orange powder

Uses

acetylcholinesterase inhibitor

Uses

Primaquine diphosphate is an established antimalarial drug used in the treatment of persistent liver forms of P. vivax or P. ovale infection for its ability to kill late-stage gametocytes and hypnozoites. In historical terms, this aminoquinoline was the stimulus for the discovery of glucose-6-phosphate (G6P) dehydrogenase deficiency as it induced hemolytic anemia in patients lacking the G6P-metabolizing enzyme.

Uses

Antimalarial.

brand name

Primaquine (Sanofi Aventis).

Biological Activity

primaquine, an 8-aminoquinoline, is introduced as a curative antimalarial agent in 1950. since then, the drug has been applied extensively to against the exoerythrocytic stage of malaria. it is demonstrated tthat primaquine, by binding to nucleic acids, could therefore block protein synthesis, alter lipid synthesis and interact with biological membranes. [1]

Clinical Use


Treatment of malaria (Plasmodium vivax and Plasmodium ovale), in combination with chloroquine
Treatment of Pneumocystis jiroveci pneumonia (PCP), in combination with clindamycin

in vitro

chicken embryo cells (cec) model were adopted to investigate the effect of primaquine on newcastle disease virus replication. it was found that virus-induced hemadsorption was inhibited by primaquine in a dose-dependent manner and was completely suppressed by primaquine 250 g/ml. viral ribonucleic acid (rna) synthesis was found to be suppressed when primaquine was added early in the virus replication cycle. whereas, when the drug was added late in the cycle, rna synthesis was stimulation. [1]

in vivo

primaquine liposomes were labelled by 99mtc and injected intravenously to swiss albino mice. after injection, the major accumulation organ of liposomes was liver followed by spleen, pancreas, lungs and the others. findings also suggested that primaquine could block the eradication of the parasites and prevent relapse by destruction of the exoerythrocytic liver stages. [2]

Drug interactions

Potentially hazardous interactions with other drugs
Antimalarials: avoid concomitant use with artemether/lumefantrine.

Metabolism

Rapidly metabolised in the liver. Its major metabolite carboxyprimaquine accumulates in the plasma on repeated dosage but possesses less antimalarial activity than the parent compound. Little unchanged drug is excreted in the urine.

Purification Methods

It forms yellow crystals from 90% aqueous EtOH and is moderately soluble in H2O. The oxalate salt has m 182.5-185o (from 80% aqueous EtOH), and the free base is a viscous liquid b 165-170o/0.002mm, 175-177o/2mm. [Elderfield et al. J Am Chem Soc 68 1526 1964, Elderfield et al. J Am Chem Soc 77 4817 1955, Beilstein 22 III/IV 5817.]

References

[1]burdick jr and durand dp. primaquine diphosphate: inhibition of newcastle disease virus replication. antimicrob agents ch. 1974 oct 15; 6(4): 460-4.
[2]aricat b, ozert ay, ercans mt and hincalt aa. characterization, in vitro and in vivo studies on primaquine diphosphate liposomes. j. microencapsulation. 1995; 12(5): 469-85.
[3]soto j, toledo j, rodriquez m, sanchez j, herrera r, padilla j and berman j. double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune colombian soldiers. clin infect dis. 1999 jul; 29: 199-201.

Primaquine diphosphateSupplier

Hubei widely chemical technology Co., Ltd. Gold
Tel
027-83778895 18602735115
Email
18602735115@163.com
Wuhan Dingxintong Pharmaceutical Co. , Ltd. Gold
Tel
027-027-83984790 17720532645
Email
t17720532645@163.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Changzhou Sunchem Pharmaceutical Chemical Material Co.,Ltd.
Tel
0519-85195575 15861192208
Email
850305@sunkechem.com
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
4006608290; 18621169109
Email
market03@meryer.com